Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Galectin Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapies that target galectins, a family of carbohydrate-binding proteins implicated in fibrosis, inflammation, and cancer. The company operates within the biopharmaceutical and life sciences industries, with a primary emphasis on chronic liver disease and related complications. Its core therapeutic approach is based on inhibiting galectin-3, a protein associated with fibrotic progression and immune dysregulation.
The company’s lead product candidate, belapectin (GR-MD-02), is being developed primarily for nonalcoholic steatohepatitis (NASH) with cirrhosis and portal hypertension, a condition with limited approved treatment options. Galectin Therapeutics was originally founded in 2005 as Pro-Pharmaceuticals, Inc. and later rebranded to reflect its strategic focus on galectin-targeted drug development. Over time, the company transitioned from a broader oncology pipeline to a more concentrated focus on liver disease and fibrosis-driven indications.
Business Operations
Galectin Therapeutics operates as a single-segment biopharmaceutical company, generating no commercial revenue and relying on capital raises to fund research and development activities. Its operations are centered on preclinical research, clinical trial execution, regulatory strategy, and intellectual property management related to galectin inhibitors. The company does not currently manufacture products for sale and instead outsources clinical trial operations and manufacturing to third-party contractors.
The company’s primary asset is belapectin, which has advanced through multiple Phase 2 clinical studies. Research and development activities are conducted predominantly in the United States, with clinical trials involving both domestic and international investigational sites. Galectin Therapeutics maintains a focused asset portfolio and does not report material operating subsidiaries or revenue-generating joint ventures.
Strategic Position & Investments
Strategically, Galectin Therapeutics is focused on advancing belapectin into later-stage clinical development for portal hypertension in NASH cirrhosis, an area with high unmet medical need and limited therapeutic competition. The company’s development strategy emphasizes disease subsets where galectin-3 inhibition has shown measurable clinical and biomarker-based effects, particularly in patients without advanced esophageal varices.
The company has historically invested primarily in internal research and development rather than large-scale acquisitions. Its intellectual property portfolio includes issued patents and pending applications covering galectin inhibition technologies and therapeutic uses. Beyond liver disease, galectin biology provides optionality for future expansion into oncology and other fibrotic or inflammatory conditions, though these areas remain secondary to its current strategic focus.
Geographic Footprint
Galectin Therapeutics is headquartered in the United States, with its principal executive offices located in Massachusetts. The company’s operational footprint is relatively limited, reflecting its clinical-stage status, and consists primarily of corporate management and research oversight functions.
Despite its small physical presence, the company maintains an international reach through global clinical trial sites, including locations in North America, Europe, and select international markets. These international activities are conducted through contract research organizations and clinical collaborators rather than wholly owned foreign subsidiaries.
Leadership & Governance
Galectin Therapeutics is led by an executive team with experience in biotechnology, clinical development, and public company management. The leadership emphasizes a science-driven strategy focused on disciplined clinical execution and capital efficiency, aligned with advancing belapectin toward regulatory milestones.
Key members of leadership include:
- Joel Lewis – Chief Executive Officer
- Richard Uihlein – Chief Financial Officer
- John A. Raschiatore – Chief Operating Officer
- David Platt – Chief Scientific Officer
The company is governed by a board of directors with backgrounds in biotechnology, finance, and healthcare, providing oversight on clinical strategy, risk management, and long-term value creation.